# Thierry André

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/thierry-andre/

## Facts

| Field | Value |
| --- | --- |
| Citations | 59,232 |
| Field | Colorectal Cancer Treatments and Studies |
| h-index | 102 |
| i10-index | 415 |
| Last Known Institution | Centre National de la Recherche Scientifique |
| OpenAlex ID | https://openalex.org/A5079480540 |
| ORCID iD | https://orcid.org/0000-0002-5103-7095 |
| Works | 1,089 |

## Researcher papers

- [Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study](https://scholariq.org/papers/nivolumab-in-patients-with-metastatic-dna-mismatch-repair-deficient-or/)
- [Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer](https://scholariq.org/papers/durable-clinical-benefit-with-nivolumab-plus-ipilimumab-in-dna-mismatch-repair/)
- [Duration of Adjuvant Chemotherapy for Stage III Colon Cancer](https://scholariq.org/papers/duration-of-adjuvant-chemotherapy-for-stage-iii-colon-cancer/)
- [2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer](https://scholariq.org/papers/2019-international-clinical-practice-guidelines-for-the-treatment-and/)
- [Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study](https://scholariq.org/papers/clinical-features-and-prognostic-factors-of-listeriosis-the-monalisa-national/)
- [Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies](https://scholariq.org/papers/impact-of-chemoradiotherapy-after-disease-control-with-chemotherapy-in-locally/)
- [Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study](https://scholariq.org/papers/can-chemotherapy-be-discontinued-in-unresectable-metastatic-colorectal-cancer/)
- [Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial](https://scholariq.org/papers/three-versus-6-months-of-oxaliplatin-based-adjuvant-chemotherapy-for-patients/)

## Researcher topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Genetic factors in colorectal cancer](https://scholariq.org/topics/genetic-factors-in-colorectal-cancer/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Colorectal Cancer Surgical Treatments](https://scholariq.org/topics/colorectal-cancer-surgical-treatments/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

## Researcher university

- [Centre National de la Recherche Scientifique](https://scholariq.org/institutions/centre-national-de-la-recherche-scientifique/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.